Shilpa Medicare has become a high-growth oncology/specialty

1. Oncology + specialty formulations: Shilpa is expanding from APIs into higher-value finished formulations and complex injectable products. 2. Biologics/biosimilars: The company has several programmes, including nivolumab, pembrolizumab, daratumumab and dupilumab. It also signed an agreement with Orion to develop and supply a nivolumab biosimilar for Europe. 3. New Oeris approval: On September 11, Shilpa received final SEC approval for Oeris, an extended-release ondansetron injection designed to provide up to 120 hours of antiemetic protection for chemotherapy patients. This is an important new-product opportunity in oncology supportive care. 4. CDMO opportunity: Shilpa is increasingly targeting complex molecules such as HPAPIs, peptides, ADCs, PROTACs and oligonucleotides. Its new Shilpa CDMO platform is expected to be formally launched at CPHI Milan in October 2026.